Chardan Capital Maintains Buy on Intellia Therapeutics, Lowers Price Target to $107
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) but lowers the price target from $111 to $107.
June 13, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital maintains a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) but lowers the price target from $111 to $107.
The news of Chardan Capital maintaining a Buy rating on Intellia Therapeutics is positive for the stock. However, the lowering of the price target from $111 to $107 may have a neutralizing effect on the stock price in the short term, as it indicates a slightly reduced growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100